New study reveals investigational compound helps bone mineral density
ATHENS, Greece New data from a phase 3 study has shown an investigational osteoporosis drug from Eli Lilly & Co. to increase bone mineral density more than a drug already on the market.
The 320-patient study of arzoxifene found that it increased BMD in the lumbar spine, total hip and femoral neck better than Lilly’s raloxifene, which the company markets as Evista. Data from the study were presented at the annual meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
“The significant increases in BMD and suppression of markers of bone turnover seen in these data show the potential benefits of arzoxifene for the treatment of osteoporosis in postmenopausal women,” said Jose Zanchetta, a study investigator and specialist at the Metabolic Research Institute in Buenos Aires, Argentina. “I’m encouraged by these results and interested in seeing the next phase 3 data for arzoxifene.”
Evista had sales of $700.5 million in 2008, according to Lilly financial data.
Major drug co. seeks to improve health care in China
NEW YORK A U.S. drug maker is collaborating with a microfinance company to find ways to expand health care among the poor in China.
Pfizer announced that it would work with PlaNet Finance to conduct an in-depth research project on the health care needs of China’s working poor. The study will examine availability of medicines, patient purchasing patterns and levels of access to healthcare services.
“Pfizer’s partnership with PlaNet Finance is aligned with the strategy to expand our geographic reach across China,” said Jean-Michel Halfon, Pfizer Emerging Markets Business Unit president and general manager. “I am extremely confident that this partnership will also achieve the broader aim of identifying unique and workable solutions for the diverse medical needs of patients in emerging markets.”
NCFPDP announces the formation of healthcare standards organization
SCOTTSDALE, Ariz. An organization recognizing prescription programs announced Thursday the formation of an association to develop healthcare standards.
The National Council For Prescription Drug Programs said it would form the Standards Charter Organization, a collaboration of U.S. healthcare standards development organizations.
The goals of the new organization, which began to take shape last year, are developing an executive forum and process for senior leadership of the U.S. healthcare standards development community to have strategic and tactical dialogue, planning and collaboration; and to unify and harmonize healthcare industry standards to meet the interoperability and standards definition needs of all healthcare stakeholders.
“The healthcare industry has made great use of information technology to improve capabilities and reduce costs, but little work has been done amongst individual standards development organizations and affiliate organizations to integrate their standards into a seamless interoperable unit,” SCO chairman and SVP of the NCPDP John Klimek said in a statement. “Through the SCO and the foundational work accomplished in its summits over the past year, various industry standards development organizations and affiliate organizations are actively working together on methods to remove barriers and improve capabilities and efficiencies, which will result in more cost-effective healthcare and ultimately better healthcare outcomes.”